研究单位：[1]Jiangsu HengRui Medicine Co.,Ltd.[2]Xuanwu Hospital Beijing,Capital Medical University
研究目的：
The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects.Subjects will take the SHR6390 on Day1 and Day22 , and from Day8 to Day26 take the efavirenz.
